Brain metastases are a common problem in patients with EGFR-mutated non-small cell lung cancer (NSCLC), occurring in about ...

Targeting the EGF receptor has shown some statistical significant improvements when using erlotinib in addition to gemcitabine; however, the clinical improvement is marginal. The angiogenesis ...

For the first time, NICE has recommended an innovative new treatment to help stop babies, children and young people who are undergoing cancer treatment from losing their hearing. We’ve issued final ...

There are several EGFR-targeting TKIs already on the market for NSCLC – including AstraZeneca's Tagrisso (osimertinib) and Roche's Tarceva (erlotinib) – but none are specifically approved to ...

Patients are significantly more likely to experience treatment-related cardiac events with osimertinib than with other EGFR TKIs, data suggest.

The management of alcoholic pancreatitis is mostly reactive; little is done to prevent disease progression. It is time for physicians to pay attention to the root cause of the condition—that is ...

Clinical trial evidence shows treatment with Tagrisso stalled cancer growth for around 18.9 months compared with 10.2 months in people who are treated with Roche’s Tarceva (erlotinib ...

Clinical molecularly targeted chemoprevention has surged forward since the late 1990s, with several targeted agents that prevent cancers, intraepithelial neoplasias and/or microbial infections ...

Bone cancer is when cells in your bones grow out of control. Usually, when you have bone cancer, it comes from another cancer that has spread to your bones or metastatic bone cancer. But ...